R01HD102975
Project Grant
Overview
Grant Description
NEURODEV KENYA: Characterizing the Epidemiology and Etiology of Developmental Disorders on the Kenyan Coast - Project Summary/Abstract.
The NEURODEV KENYA data set will provide an unprecedented opportunity to study the etiology of neurodevelopmental disorders (NDDs) in East Africa, and create a research resource of international value. It will be the first large-scale NDD collection in a rural African setting that is deeply phenotyped and genetically informative, and all data and materials will be made publicly available.
In this application, we propose to conduct extensive analysis of NEURODEV KENYA’s genetic and phenotypic data, beginning in the award’s second year. The analyses will leverage the rich environment at KEMRI and will be intertwined with our proposed capacity building activities (AIM 3).
Through our capacity building activities, we will provide structured training in genetics and genetic data analysis, determine whether to introduce a lymphoblastic cell line (LCL) protocol into NEURODEV KENYA, and determine how to ethically include adults with ID.
We will share all data (e.g. phenotypes, genotypes), and materials (e.g. DNA from blood, possibly LCLs) through the NIH. We will also share outputs through international consortia and a new African NDD research network formalized through this award (AIM 4).
The NEURODEV KENYA data set will provide an unprecedented opportunity to study the etiology of neurodevelopmental disorders (NDDs) in East Africa, and create a research resource of international value. It will be the first large-scale NDD collection in a rural African setting that is deeply phenotyped and genetically informative, and all data and materials will be made publicly available.
In this application, we propose to conduct extensive analysis of NEURODEV KENYA’s genetic and phenotypic data, beginning in the award’s second year. The analyses will leverage the rich environment at KEMRI and will be intertwined with our proposed capacity building activities (AIM 3).
Through our capacity building activities, we will provide structured training in genetics and genetic data analysis, determine whether to introduce a lymphoblastic cell line (LCL) protocol into NEURODEV KENYA, and determine how to ethically include adults with ID.
We will share all data (e.g. phenotypes, genotypes), and materials (e.g. DNA from blood, possibly LCLs) through the NIH. We will also share outputs through international consortia and a new African NDD research network formalized through this award (AIM 4).
Awardee
Funding Goals
TO CONDUCT AND SUPPORT LABORATORY RESEARCH, CLINICAL TRIALS, AND STUDIES WITH PEOPLE THAT EXPLORE HEALTH PROCESSES. NICHD RESEARCHERS EXAMINE GROWTH AND DEVELOPMENT, BIOLOGIC AND REPRODUCTIVE FUNCTIONS, BEHAVIOR PATTERNS, AND POPULATION DYNAMICS TO PROTECT AND MAINTAIN THE HEALTH OF ALL PEOPLE. TO EXAMINE THE IMPACT OF DISABILITIES, DISEASES, AND DEFECTS ON THE LIVES OF INDIVIDUALS. WITH THIS INFORMATION, THE NICHD HOPES TO RESTORE, INCREASE, AND MAXIMIZE THE CAPABILITIES OF PEOPLE AFFECTED BY DISEASE AND INJURY. TO SPONSOR TRAINING PROGRAMS FOR SCIENTISTS, DOCTORS, AND RESEARCHERS TO ENSURE THAT NICHD RESEARCH CAN CONTINUE. BY TRAINING THESE PROFESSIONALS IN THE LATEST RESEARCH METHODS AND TECHNOLOGIES, THE NICHD WILL BE ABLE TO CONDUCT ITS RESEARCH AND MAKE HEALTH RESEARCH PROGRESS UNTIL ALL CHILDREN, ADULTS, FAMILIES, AND POPULATIONS ENJOY GOOD HEALTH. THE MISSION OF THE NICHD IS TO ENSURE THAT EVERY PERSON IS BORN HEALTHY AND WANTED, THAT WOMEN SUFFER NO HARMFUL EFFECTS FROM REPRODUCTIVE PROCESSES, AND THAT ALL CHILDREN HAVE THE CHANCE TO ACHIEVE THEIR FULL POTENTIAL FOR HEALTHY AND PRODUCTIVE LIVES, FREE FROM DISEASE OR DISABILITY, AND TO ENSURE THE HEALTH, PRODUCTIVITY, INDEPENDENCE, AND WELL-BEING OF ALL PEOPLE THROUGH OPTIMAL REHABILITATION.
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Boston,
Massachusetts
021142621
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have increased 8549% from $30,000 to $2,594,590.
The General Hospital Corporation was awarded
NEURODEV KENYA: Epidemiology & Etiology of Developmental Disorders on Kenyan Coast
Project Grant R01HD102975
worth $2,594,590
from the National Institute of Child Health and Human Development in September 2021 with work to be completed primarily in Boston Massachusetts United States.
The grant
has a duration of 5 years and
was awarded through assistance program 93.865 Child Health and Human Development Extramural Research.
The Project Grant was awarded through grant opportunity Global Brain and Nervous System Disorders Research Across the Lifespan (R01 Clinical Trials Optional).
Status
(Ongoing)
Last Modified 9/24/25
Period of Performance
9/30/21
Start Date
8/31/26
End Date
Funding Split
$2.6M
Federal Obligation
$0.0
Non-Federal Obligation
$2.6M
Total Obligated
Activity Timeline
Subgrant Awards
Disclosed subgrants for R01HD102975
Transaction History
Modifications to R01HD102975
Additional Detail
Award ID FAIN
R01HD102975
SAI Number
R01HD102975-99931368
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Nonprofit With 501(c)(3) IRS Status (Other Than An Institution Of Higher Education)
Awarding Office
75NT00 NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development
Funding Office
75NT00 NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development
Awardee UEI
FLJ7DQKLL226
Awardee CAGE
0ULU5
Performance District
MA-08
Senators
Edward Markey
Elizabeth Warren
Elizabeth Warren
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| National Institute of Child Health and Human Development, National Institutes of Health, Health and Human Services (075-0844) | Health research and training | Grants, subsidies, and contributions (41.0) | $998,484 | 94% |
| John E. Fogarty International Center, National Institutes of Health, Health and Human Services (075-0819) | Health research and training | Grants, subsidies, and contributions (41.0) | $60,000 | 6% |
Modified: 9/24/25